Maynard Um
-
-
-
-
-
-
-
Incyte (INCY) PT Raised to $150 at Guggenheim
-
-
-
-
-
-
-
Incyte (INCY) Reiterated at Market Perform by Citizens on Updated VIVID-3 Data
-
-
-
-
-
-
-
Incyte settles CMS lawsuit over Opzelura Medicaid rebate rules
-
-
-
-
-
-
-
Incyte (INCY) PT Raised to $107 at Oppenheimer
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Incyte (INCY)
-
-
-
-
-
-
-
MINJUVI approved in Australia for relapsed follicular lymphoma treatment
-
-
-
-
-
-
-
Incyte (INCY) PT Lowered to $94 at UBS
-
444,171 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

